Continuing Education Activity

Acid-base disorders, particularly metabolic acidosis, found commonly in hospitalized patients and patients with chronic medical conditions, represent a critical diagnostic and therapeutic challenge in clinical practice. This activity reviews the physiologic principles underlying acidosis, distinguishing between respiratory and metabolic origins, and identifying mixed acid-base disturbances. Through a systematic approach to interpreting arterial or venous blood gases and calculating the anion gap, participants will develop the skills necessary to accurately diagnose high anion gap and normal anion gap metabolic acidosis.

Additionally, this course explores the diverse etiologies of acidemia using structured mnemonics such as “GOLD MARKeT” and “CAT MUDPILES,” and apply diagnostic reasoning to differentiate causes such as lactic acidosis, ketoacidosis, renal failure, and toxic ingestions. The activity also addresses non–anion gap acidosis from gastrointestinal losses, renal tubular disorders, and iatrogenic sources, as well as clinical evaluation strategies, and evidence-based treatment options based on the underlying causes. This activity for healthcare professionals is designed to enhance the learner's competence in identifying acid-base disturbances, treating acute complications, performing the recommended evaluation, delivering individualized, patient-centered care, and implementing an appropriate interprofessional approach when managing this condition to improve outcomes in critically ill and medically complex patients.

Objectives:

• Assess the causes of high anion gap and normal anion gap metabolic acidosis.
• Determine the pathophysiology of both high anion gap and normal anion gap metabolic acidosis.
• Implement systematic evaluation of acid-base disorders using tools such as the corrected anion gap, delta/delta ratio, urinary anion gap, and blood gas analysis
• Apply interprofessional team strategies to improve care coordination and outcomes in patients with high anion gap metabolic acidosis

Introduction

Acidosis can be broadly classified into metabolic and respiratory etiologies, distinguished by their primary derangements. Taking a systematic approach to calculate each component of the acid-base physiology is crucial to arriving at the final diagnosis, especially in cases of mixed acid-base disorders.

Metabolic acidosis is characterized by a reduction in serum bicarbonate (HCO₃) and a compensatory decrease in arterial pCO₂, whereas respiratory acidosis results from elevated arterial pCO₂ due to hypoventilation, with a secondary renal retention of bicarbonate to compensate.[1][2] Arterial blood gas (ABG) analysis, in conjunction with serum electrolytes, helps differentiate these disorders. A low pH with low bicarbonate (HCO₃) suggests metabolic acidosis, while a low pH with elevated pCO₂ indicates respiratory acidosis.[3] Acidemia is defined as a blood pH below 7.35.[4] Severe acidemia (pH <7.2) is associated with profound clinical consequences, including systemic vasodilation, reduced myocardial contractility and mean arterial pressure (MAP), diminished responsiveness to catecholamines and vasopressors, cardiac arrhythmias, hyperkalemia, insulin resistance, and altered mental status.[5] Given the invasiveness of ABGs, venous blood gases (VBGs) are sometimes used instead; the pH in VBGs is 0.02 to 0.05 lower than ABGs, and the PCO2 of VBG is about 4 to 6 mm Hg higher than that of ABG, but in severe hypoperfusion, VBG values can significantly vary.[6]

Metabolic acidosis can be further classified based on the anion gap, which is calculated as the anion gap = (Na + K) – (Cl + HCO₃). The fundamental concept behind this is that to maintain homeostasis, the number of cations must equal the number of anions, so the anion gap measures the amount of unmeasured anions (which in normal physiological states is albumin). If the unmeasured anion/cation is paired with one of the components measured in the anion gap, the anion gap value will shift accordingly. Potassium is often left out of the equation, given its minimal contribution, simplifying the equation to anion gap = (Na) – (Cl + HCO₃).[7] In high anion gap metabolic acidosis (HAGMA), abnormal or excess acids, eg, lactate, ketones, or toxic metabolites, accumulate, increasing unmeasured anions and thus widening the anion gap. A normal anion gap is 8 to 12 (if potassium is included, normal values are 12 to 16). Of note, venous HCO₃ values are usually used to measure anion gap rather than values from the ABG, as venous values also account for carbonic acid and dissolved CO₂. The venous values are typically 2 to 4 mEq/L higher than the arterial values.[8]

Conversely, in normal anion gap metabolic acidosis (NAGMA), also known as hyperchloremic acidosis, the increase in chloride balances the decrease in bicarbonate, maintaining electroneutrality with no net change in the anion gap.[9] Some etiologies (eg, renal insufficiency) can cause both gap and non–anion gap metabolic acidosis, depending on the clinical situation.

Etiology

High Anion Gap Metabolic Acidosis

HAGMA can be a life-threatening acid-base disorder resulting from the accumulation of unmeasured anions in the plasma. These unmeasured anions arise from various exogenous toxins or endogenous metabolic products. Recognizing and addressing the underlying cause is critical for management. The following mnemonic, “GOLD MARKeT,” is widely used to categorize the major causes of HAGMA, each associated with distinct pathophysiological mechanisms:

• G – Glycols (ethylene glycol, propylene glycol): Ethylene glycol and propylene glycol are metabolized into organic acids, including glycolic acid, oxalic acid, and lactic acid. These acids increase the unmeasured anion load, resulting in HAGMA. Ethylene glycol toxicity additionally causes renal tubular injury through oxalate crystal deposition, exacerbating acid-base disturbances and renal dysfunction.[1]
• O – Oxoproline (5-oxoproline or pyroglutamic acid): Chronic acetaminophen use or certain antibiotic regimens can disrupt the gamma-glutamyl cycle, leading to the accumulation of 5-oxoproline. This organic acid accumulation is particularly pronounced in patients with malnutrition or chronic illness, contributing to metabolic acidosis with an elevated anion gap.[10] Possible exposures are through IV lorazepam and e-cigarett/e-vapor products.[11][12]
• L – Lactic Acid (L-lactic acidosis): Common in shock, sepsis, or mitochondrial dysfunction, L-lactic acidosis results from increased anaerobic metabolism. Lactic acid is a strong organic acid that contributes significantly to the anion gap.[13] Lactic acidosis can result from decreased oxygen delivery to organs (eg, sepsis, shock, emboli) or impaired oxygen utilization or lactate accumulation (eg, liver failure, kidney insufficiency, genetic abnormalities, metformin, linezolid, cocaine).[13] Notably, at physiologic pH, lactic acid is fully dissociated and exists in the deprotonated form of lactate. So when "lactic acid" levels are measured, the lactate anion is actually being measured. Please see StatPearls' companion reference, "Lactic Acidosis," for further information.
• D – D-lactic acid: D-lactic acidosis arises from abnormal bacterial fermentation of carbohydrates in the gastrointestinal tract, notably in patients with short bowel syndrome. D-lactate, an isomer not efficiently metabolized by humans, accumulates and leads to HAGMA.[14]
• M – Methanol: Methanol poisoning results in the hepatic metabolism of methanol to formic acid, a highly toxic metabolite. The accumulation of formic acid causes increased unmeasured anions, contributing to metabolic acidosis and clinical manifestations such as visual disturbances and central nervous system depression.[15]
• A – Aspirin (salicylates): Salicylates uncouple oxidative phosphorylation, leading to lactic acid and ketoacid accumulation, causing HAGMA. Early toxicity often presents with concurrent respiratory alkalosis due to respiratory center stimulation.[16]
• R – Renal failure and rhabdomyolysis: Impaired renal function diminishes the excretion of sulfate, phosphate, and other organic acids, causing retention of unmeasured anions and metabolic acidosis. Rhabdomyolysis releases intracellular acids and phosphate, often leading to acute kidney injury.[17]
• Ke – Ketones (diabetic, alcoholic, starvation ketoacidosis): In states of insulin deficiency or prolonged fasting, ketone bodies (acetoacetate and β-hydroxybutyrate) accumulate. These acidic metabolites increase the anion gap and contribute to metabolic acidosis in diabetic ketoacidosis, alcoholic ketoacidosis, and starvation.[18]
• T - Toluene:  Toluene can cause gap or non–anion gap metabolic acidosis. Most commonly, toluene causes non–anion gap metabolic acidosis, but it can also cause anion gap metabolic acidosis less commonly. Toluene typically causes a distal renal tubular acidosis picture; however, related to hippurate accumulation, toluene can also produce an anion gap metabolic acidosis. Toluene toxicity can occur from occupational exposure to paint, paint thinner, and petrol, as well as from abuse of glue sniffing.[19][20]

Metformin presents a well-recognized cause of lactic acidosis. Used for over 60 years, metformin is one of the most commonly prescribed drugs for diabetes and prediabetes. Due to primarily being cleared by the kidneys, metformin is contraindicated when eGFR is lower than 30 mL/min/1.73 m². Metformin blocks aerobic glycolysis in the mitochondria, thereby increasing anaerobic glycolysis and lactic acid accumulation.[21] The risk of this may be increased with concurrent use of sodium-glucose cotransporter 2 (SGLT2) inhibitors.[22] Please see StatPearls' companion reference, "Metformin-Associated Lactic Acidosis."

 Another mnemonic for anion gap metabolic acidosis differential is "CAT MUDPILES" which represents the following etiologies:

• C: Cyanide and carbon monoxide poisoning
• A: Arsenic
• T: Toluene
• M: Methanol, Metformin
• U: Uremia
• D: Diabetic ketoacidosis
• P: Paraldehyde
• I: Iron, INH
• L: Lactate
• E: Ethylene glycol
• S: Salicylates

Non–Anion Gap Metabolic Acidosis

Non–anion gap metabolic acidosis is primarily caused by the loss of bicarbonate or the gain of chloride, and the main causes of this condition are diarrhea and renal tubular acidosis. Additional and less common etiologies include Addison disease, ureterosigmoid or pancreatic fistulas, carbonic anhydrase use, and chronic laxative use.[23] Other exogenous causes include the addition of hydrochloric acid (or substances with HCl as a metabolite), which causes a compensatory loss of bicarbonate, TPN administration, or administration of normal saline as described below.[13] Rarely are genetic syndromes associated with renal tubular acidosis.[23] 

Renal tubular acidosis primarily causes NAGMA by decreased ammonium (NH₄) production, which is needed for bicarbonate regeneration. In the absence of sufficient NH₄, anions produced from metabolism and dietary intake are excreted with Na or K, causing avid retention of Na and Cl by the kidney. The Cl replaces the lost HCO₃, resulting in hyperchloremic metabolic acidosis. A similar mechanim occurs with the presence of toluene or ketoacidosis (metabolized to hippurate and ketoanions) where these anions are excreted with Na or K.[24]

Gastrointestinal causes of NAGMA include loss of pancreatic, duodenal, biliary, or intestinal fluids, which are high in HCO₃. Of the gastrointestinal causes of NAGMA, diarrhea is by far the most common, causing a lack of HCO₃ reabsorption and loss through the intestinal tract. Secretory diarrhea causes a higher incidence of NAGMA than inflammatory diarrhea, as it contains a higher concentration of HCO3. Diversion of the ureters to the ileum or sigmoid colon after bladder removal (eg, bladder cancer) can also cause NAGMA, as the intestine will reabsorb NH₄ and Cl and secrete HCO₃.[23][24]

A common cause of non–anion gap metabolic acidosis is the administration of large amounts of normal saline. Examples would be intraoperative administration, shock, or burn victims.[25][26][27] This is related in part to the chloride load (the concentration in normal saline being 154 mEq/L, while about 100 to 106 mEq/L in plasma), as well as a dilutional effect, since normal saline contains no bicarbonate. NAGMA is also common in children with diarrhea who receive large volumes of normal saline.[28] Normal saline is associated with hyperchloremic metabolic acidosis in both hospitalized and healthy individuals, as well as children and adults. In addition, hyperchloremia itself is associated with increased mortality.[29][30] Multiple studies have shown that infusion of high-chloride fluid reduces renal perfusion through vasoconstriction and also decreases GFR. Some evidence also suggests that chloride-rich fluids may impair coagulation. For these reasons, many experts now suggest using fluids with a more physiologic chloride concentration, eg, lactated Ringer's or plasmalyte.[26][31]

A rare cause of non–anion gap metabolic acidosis is cholestyramine. This medication is a bile acid sequestrant used for hypercholesterolemia. It exchanges chloride anions for bile acids in the ileum, resulting in the excretion of bile acids through the feces. This exchange results in the excretion of bicarbonate and the reabsorption of chloride through the duodenal apical brush border bicarbonate/chloride antiporter. Usually, the kidney can compensate for this by reabsorbing bicarbonate; however, in settings of renal insufficiency or aldosterone insensitivity (or antagonism), these mechanisms are not available, and metabolic acidosis will ensue.[32][33]

Total parenteral nutrition (TPN) can also cause non–anion gap metabolic acidosis. If TPN does not contain acetate as a buffer, no source of bicarbonate. In addition, some amino acids (particularly arginine and lysine) are metabolized to HCl.[23][24]

Addison disease, or medications that block the action of aldosterone, can cause hyperchloremic metabolic acidosis. Aldosterone acts on the epithelial Na channel, located on the apical side of the distal convoluted tubule and collecting duct of the nephron, and the basolateral Na/K ATPase pump. Through these mechanisms, sodium is reabsorbed from the tubular lumen, and potassium and hydrogen ions are excreted. The resulting pattern is similar to Type IV RTA. Acquired hypoaldosteronism may be more common than previously thought, especially in hospitalized patients aged older than 65 and patients on multiple medications.[34][35]

Epidemiology

HAGMA is a prevalent acid-base disturbance among critically ill patients. Studies show that HAGMA is commonly encountered in intensive care units and is often related to conditions, eg, lactic acidosis, ketoacidosis, renal failure, toxin ingestion, and many other causes. Although the majority of ICU patients present with metabolic alkalosis, those with metabolic acidosis had higher mortality. Lactic acidosis, sepsis, and multiorgan failure were contributing factors.[36]

The clinical significance of HAGMA is underscored by its association with increased mortality rates. Elevated anion gap levels correlate strongly with higher in-hospital, 30-day, and 90-day mortality in critically ill patients, highlighting their prognostic value.[37] The presence of unmeasured anions, eg, lactate and ketones, reflects underlying pathophysiological states (eg, sepsis and renal failure).[38] Chronic acetaminophen use or certain antibiotic regimens can disrupt the gamma-glutamyl cycle, leading to the accumulation of 5-oxoproline. This organic acid accumulation is particularly pronounced in patients with malnutrition or chronic illness, contributing to metabolic acidosis with an elevated anion gap.

In terms of NAGMA, a comprehensive review found that 19% to 41% of patients in ICU settings demonstrated non–anion gap metabolic acidosis. In addition, 20% to 55% of people with chronic renal insufficiency had a NAGMA.[24]

Pathophysiology

High Anion Gap Metabolic Acidosis

Anion gap

The anion gap compares sodium concentration (and sometimes potassium) with the sum of chloride and bicarbonate concentrations. The main negatively charged anion causing the anion gap is albumin. Calculating the anion gap helps distinguish between HAGMA and NAGMA, thereby aiding in determining the etiologies. The change in anion gap should then be compared to the change in bicarbonate to evaluate for further acid-base disorders. Whenever possible, the change in anion gap should be measured against the patient's baseline anion gap, which is typically obtained when the patient is relatively healthy.[24]

Compensatory respiratory alkalosis

Metabolic acidosis causes a compensatory hyperventilation response within 12 to 24 hours, which can be calculated through Winter's formula: PaCO₂ = (1.5 x HCO₃ +8 ) ±2. The minimum PaCO2 level that can be reduced to is 8 to 12 mEq/L. Conventionally, the bicarbonate level used is from a venous blood sample, which is generally 2 to 4 mEq/L higher than an arterial sample.[8] An anion gap >18 almost always indicates the presence of an organic acid. Rarely, the accumulation of phosphates and sulfates in kidney failure can create a large anion gap, but the gap is rarely >18.[13]

Hypoalbuminemia

The albumin level must also be taken into account because albumin is a negatively charged protein; therefore, albumin loss leads to the retention of negatively charged ions, eg, bicarbonate and chloride, which can underestimates the severity of the anion gap.[39] For each 1 g/100 mL below the normal value of 4.5 g/100 mL, the anion gap falls by about 2.5 mEq/L. The following formula can estimate this correction: 

[anion gap](corrected) = [anion gap](measured) + 2.5 × (4.0 - [albumin]) [8][40]

This correction ensures more accurate identification of HAGMA, particularly in patients with hypoalbuminemia due to conditions, eg, sepsis, malnutrition, liver disease, or chronic illness.[38] For example, a patient with a measured anion gap of 10 and an albumin of 2.0 g/dL would have a corrected anion gap of 15, indicating a true HAGMA that might otherwise be overlooked. 

Delta/delta or delta gap

After calculating the anion gap and determining that the patient has HAGMA, the next critical step is to calculate the delta gap (also called the delta-delta) to evaluate for mixed acid-base disorders. The delta gap compares the change in the anion gap to the change in serum bicarbonate, based on the principle that in pure HAGMA, the increase in the anion gap should be approximately equal to the decrease in bicarbonate. The delta gap ratio is calculated as: Δanion gap / ΔHCO₃ = (corrected anion gap − 12) / (24 − measured HCO₃), where 12 mEq/L is the upper limit of the normal anion gap and 24 mEq/L is the normal bicarbonate level. The following interpretations of this ratio helps identify concurrent acid-base disturbances:

• A ratio between 1 and 2 generally indicates a pure HAGMA.
• A ratio <1 suggests a concurrent normal anion gap (non–anion gap) metabolic acidosis.
• A ratio >2 indicates an additional metabolic alkalosis or preexisting elevated bicarbonate (see Image. Algorithm for Assessing Anion Gap and Non–Anion Gap Acidosis).

Calculating the delta gap ratio is crucial, particularly in critical care settings where multiple disorders may coexist.[7][9][41]

Osmolar gap

The osmolar gap is a valuable tool in evaluating HAGMA, particularly in cases of suspected toxic alcohol ingestion. Osmolar gaps can also be caused by iatrogenic factors, eg, radiocontrast administration, sorbitol (from TPN), maltose, dextrose, or mannitol. Osmolar gap is calculated by subtracting the calculated serum osmolality from the measured serum osmolality, using the following formula: 

Calculated osmolality = 2 × (Na + K) + (glucose ÷ 18) + (BUN ÷ 2.8) + (ethanol ÷ 4.6)

A normal osmolar gap is typically <10 mOsm/kg, while an elevated gap (>10 mOsm/kg) suggests the presence of exogenous osmoles, including methanol, ethylene glycol, or isopropanol.[8] The coexistence of HAGMA with an elevated osmolar gap is highly suggestive of toxic alcohol ingestion. Each toxic alcohol has characteristic metabolites and the following clinical manifestations: 

• Methanol is metabolized to formic acid and presents with altered mental status (AMS), blurry vision, dilated pupils, and papilledema.
• Ethylene glycol forms oxalic acid and can cause AMS, cranial nerve palsies, flank pain, hematuria, hypocalcemia with tetany, and calcium oxalate crystals (envelope shaped crystals) leading to acute kidney injury (AKI).
• Propylene glycol is converted to lactic acid and may cause AKI and liver injury.
• Diethylene glycol is metabolized to diglycolic acid and presents with AKI, nausea/vomiting, hepatitis, pancreatitis, neuropathy, AMS, and elevated lactate.
• Isopropyl alcohol is converted to acetone and typically causes AMS, fruity breath, pancreatitis, and elevated lactate with a normal or mildly elevated anion gap.
• Ethanol is metabolized to acetaldehyde and may result in ketoacidosis, lactic acidosis, and metabolic alkalosis due to vomiting.

Despite its utility, the osmolar gap has limitations—it may be normal early in intoxication, unreliable in rapidly evolving cases, and confounded by rare toxins like bromide.[42][43] Accurate lab interpretation and clinical context are essential, as other conditions like diabetic ketoacidosis (DKA) or sepsis can also affect the osmolar and anion gaps.

Nonanion Gap Metabolic Acidosis

In nonanion gap metabolic acidosis, gastrointestinal and renal losses of bicarbonate can be distinguished via urine anion gap analysis:

• Urine anion gap = Urine Na + Urine K – Urine Cl, if urine pH is <6.5
• Urine anion gap = Urine Na + Urine K - (Urine Cl + Urine HCO3), if urine pH is >6.5 [44]

The urine anion gap can help estimate the urinary ammonium. The urinary anion concentration decreases and can become negative if ammonium (a cation) is elevated as part of a normal adaptive renal response to an extrarenal etiology of metabolic acidosis, eg, diarrhea or another gastrointestinal source. When the urine anion gap is positive, this suggests decreased ammonium excretion, which, in the presence of metabolic acidosis, suggests renal impairment such as distal renal tubular acidosis or chronic kidney disease.[44] The urine pH is often not a reliable indicator of urine acidification, as the body will produce more ammonia to buffer the excess hydrogen in the setting of prolonged metabolic acidosis.[44]

Histopathology

Microscopy has limited utility in the evaluation of metabolic acidosis; however, an important exception is the assessment for ethylene glycol ingestion. Ethylene glycol is metabolized into toxic compounds, including oxalate, which can bind calcium to form calcium oxalate crystals. At sufficiently high toxic doses, calcium oxalate monohydrate crystals can deposit in tissues such as the kidneys and brain, and precipitate in the urine.[42] 

On urine microscopy, these calcium oxalate monohydrate crystals appear as dumbbells, spindles, ovals, or “picket fence” shapes.[45] These can be distinguished from calcium oxalate dihydrate crystals, which are classically octahedral and described as “envelope-shaped”.[3] Identifying these crystals in the urine can support the diagnosis of ethylene glycol poisoning, particularly when combined with clinical and laboratory findings, eg, elevated anion and osmolar gaps (see Image. Calcium Oxalate Dihydrate Crystals).[46]

History and Physical

Clinical History

A detailed patient history plays a crucial role in diagnosing metabolic acidosis in both hospitalized and nonhospitalized individuals. Clinicians must inquire thoroughly about medication use, including over-the-counter and ingested substances. Identifying a history of diabetes, chronic alcohol use, attempted self-harm, and gastrointestinal disturbances such as diarrhea remains essential. For hospitalized patients, documentation should include whether large volumes of normal saline or other medications were administered in the emergency department.

Comprehensive symptom assessment contributes significantly to diagnostic accuracy. Although often nonspecific, symptoms of acidosis, including anorexia, fatigue, headache, nausea, and vomiting, warrant attention. Clinicians should specifically ask about gastrointestinal symptoms, eg, diarrhea or vomiting. Signs of renal insufficiency, including nocturia, pruritus, or oliguria, should be explored.[18][47] Additionally, clinicians must consider symptoms suggestive of diabetes, eg, polyuria or polydipsia.

Physical Examination

Physical examination should include a careful review of vital signs. Hypotension may suggest volume depletion from gastrointestinal losses or a hypoaldosterone state. The presence of Kussmaul respirations—deep, labored breathing—often indicates a compensatory response to metabolic acidosis. Findings, eg, dry mucous membranes and a characteristic ketotic, chemical odor on the breath, may suggest diabetic ketoacidosis. Asterixis and changes in mental status can reflect renal insufficiency.[48] In advanced stages, metabolic acidosis may present with respiratory failure, altered consciousness, arrhythmias, and hemodynamic instability.

Evaluation

Metabolic acidosis is primarily diagnosed through a thorough history and laboratory values in plasma and urine. Initial studies that are conducted include the following:

• Basic metabolic panel (BMP)
• ABG (of VBG if the patient is not septic or severely hypoperfused)
• Lactate level
• Plasma and urine osmolarity
• Urine sodium, potassium, chloride, and bicarbonate

Evaluation of metabolic acidosis begins with assessing the pH on either a VBG or ABG analysis. A low pCO2 level in the setting of low pH indicates the presence of metabolic acidosis. Although the body initiates compensatory mechanisms, these responses rarely normalize the serum pH. Following this initial assessment, clinicians should calculate the anion gap, regardless of whether the serum pH appears close to normal. This calculation must be adjusted for the patient’s albumin level to ensure accuracy.

An elevated corrected anion gap requires further analysis, beginning with evaluation of the delta gap to assess for the presence of concurrent metabolic processes. Additionally, the osmolar gap should be measured to identify potential toxic ingestions or unmeasured solutes.

When the corrected anion gap remains within the normal range, additional urine studies become necessary. Assessment should include the urine anion gap, urine pH, and urine electrolyte concentrations. These values help differentiate between renal and gastrointestinal causes of NGMA. If the patient reports urinary, abdominal, or groin pain suggestive of renal colic, abdominal computed tomography imaging may be indicated, as nephrolithiasis may underlie or contribute to the acid-base disturbance.

Treatment / Management

Metabolic Acidosis Management

Management of metabolic acidosis begins with prompt identification and treatment of the underlying cause, eg, sepsis, while providing supportive measures including intravenous fluid resuscitation and respiratory support.[49] In cases of severe acidosis with pH below 7.1, the use of intravenous sodium bicarbonate may be considered, although its routine administration remains controversial. Findings from the BICAR-ICU multicenter randomized controlled trial demonstrated no significant mortality benefit from bicarbonate therapy in patients with severe metabolic acidosis (pH <7.2), except in those with concurrent acute kidney injury.[50]

The cautious use of sodium bicarbonate stems from its potential adverse effects, including hypernatremia, hypocalcemia, intracellular acidification, increased lactate production, and reduced myocardial contractility. Continuous renal replacement therapy (CRRT) also provides limited effectiveness in clearing lactic acid, reinforcing the importance of supportive care and targeted treatment of the underlying condition in cases of lactic acidosis.[13] 

Etiology-specific management

Treatment strategies must be tailored to the specific etiology of metabolic acidosis.

Thiamine is commonly administered in patients with lactic acidosis. When metformin-induced lactic acidosis occurs, hemodialysis may be required. Methanol undergoes hepatic metabolism to form formaldehyde, a toxic compound. Effective treatments for methanol toxicity include fomepizole—or ethanol if fomepizole is unavailable—and hemodialysis when methanol levels exceed 500 mg/L, or when severe acidemia, visual disturbances, obtundation, kidney failure, or hemodynamic instability are present. Ethylene glycol poisoning requires the same therapeutic approach.[13][51]

Management of diabetic ketoacidosis focuses on insulin therapy, continued until anion gap closure occurs. Treatment does not begin with bicarbonate, even when acidosis is present. Potassium repletion and volume restoration remain essential components of therapy. Euglycemia must be achieved before correction is considered complete. Alcoholic ketoacidosis requires thiamine supplementation and correction of electrolyte imbalances, along with volume repletion. Studies have shown no improvement in outcomes with intravenous bicarbonate administration in diabetic ketoacidosis.[13] Current guidelines from the American Diabetes Association recommend IV bicarbonate only when serum pH falls below 6.9.[52]

Salicylate toxicity, which typically presents with a combination of respiratory alkalosis and metabolic acidosis, requires rapid gastrointestinal decontamination with activated charcoal and alkalinization of the serum and urine using intravenous bicarbonate. This approach helps reduce central nervous system penetration and enhances renal excretion. Blood pH must be monitored closely during treatment to avoid alkalemia (pH >7.6). Hemodialysis becomes necessary when salicylate concentrations surpass 100 mg/dL or when patients present with obtundation or pulmonary edema.[13]

Differential Diagnosis

Differential diagnoses that should also be considered in patients with metabolic acidosis:

• Compensation for respiratory alkalosis
• Hyperkalemia
• Anion gap acidosis uncorrected for albumin level
• Hemolysis
• Laboratory errors

Prognosis

The prognosis of metabolic acidosis largely depends on the underlying cause, the severity of acidemia, and the timeliness of diagnosis and treatment. When the primary etiology is promptly identified and effectively managed—eg, in diabetic ketoacidosis, sepsis, or toxic ingestions—patients often recover fully with minimal long-term sequelae. However, delayed treatment or severe acidemia (pH <7.1) significantly increases the risk of complications, including organ failure, cardiac arrhythmias, hemodynamic instability, inflammation, and death.[27]

Acute metabolic acidosis with a pH around 7.20 has been associated with mortality rates exceeding 50% if not promptly corrected.[38] Patients with comorbidities such as chronic kidney disease (CKD) or advanced liver disease typically have a worse prognosis. In particular, studies have shown that an increased anion gap in CKD patients correlates with higher all-cause mortality and faster progression to kidney failure.[53] Overall, early recognition and coordinated interprofessional care are critical to improving outcomes in metabolic acidosis.[54]

Complications

If not promptly recognized and treated, metabolic acidosis can lead to life-threatening complications. Severe acidemia (pH <7.1) may impair myocardial contractility, cause hypotension, and significantly increase the risk of cardiac arrhythmias. Respiratory muscle fatigue can occur due to sustained compensatory hyperventilation.

In cases involving toxic ingestions (eg, methanol or ethylene glycol), complications may include irreversible organ damage, eg, blindness, acute kidney injury, or neurologic impairment. Persistent or recurrent metabolic acidosis may worsen outcomes in patients with diabetes or chronic kidney disease. Ultimately, death is a potential complication, particularly in critically ill patients or those with delayed treatment.[55]

Consultations

Consultations that may also be involved in the management of high anion gap metabolic acidosis include:

• Emergency room physicians
• Intensivists
• Internists
• Toxicologists
• Nephrologists

Deterrence and Patient Education

Preventing metabolic acidosis requires addressing modifiable risk factors and educating patients on early recognition and avoidance of triggers. Individuals with diabetes should maintain glycemic control to prevent ketoacidosis. Patients must be warned about the dangers of ingesting toxins, eg, methanol or salicylates, and must ensure proper storage. Individuals with kidney disease require regular follow-up and adherence to their treatment regimen. Medication risks (eg, metformin, isoniazid) should be reviewed, especially in renal or hepatic impairment. Patients should be taught to recognize early signs, including nausea, confusion, or rapid breathing, and to seek timely medical care.

Enhancing Healthcare Team Outcomes

Optimal management of high anion gap metabolic acidosis relies on a cohesive interprofessional strategy that brings together the expertise of physicians, advanced practitioners, nurses, pharmacists, and laboratory staff. Physicians and nurse practitioners are responsible for synthesizing clinical presentations with laboratory results—including arterial blood gas analyses, electrolyte panels, and anion gap calculations—to identify the underlying cause. Timely recognition of life-threatening etiologies such as diabetic ketoacidosis, lactic acidosis, renal failure, or toxic ingestions directs immediate and appropriate interventions. Pharmacists play a critical role in reviewing medications, identifying toxic agents like salicylates or metformin, and recommending antidotes such as fomepizole or supportive therapies. Nurses continuously monitor patient status, assess fluid balance, report signs of deterioration, and implement treatment plans with precision and accuracy. Laboratory staff provide accurate and timely data essential to clinical decision-making, allowing rapid calculation of corrected anion gaps and osmolar gaps that guide further evaluation and therapy.

Effective communication and coordinated care workflows form the foundation of safe and patient-centered management. Structured team huddles and shared clinical pathways facilitate the early identification of metabolic disturbances, thereby reducing delays in care. Defining team roles helps prevent errors, especially during critical transitions such as initiating dialysis or managing patients with multi-organ dysfunction. Advanced practitioners and physicians lead interprofessional discussions, particularly when decisions must be made about escalating care, initiating renal replacement therapy, or limiting invasive interventions. Nurses advocate for patients’ needs and preferences, while pharmacists ensure medication safety and adjust therapies based on renal or hepatic function. Involving patients and families in discussions about prognosis and treatment options ensures ethical care and aligns clinical decisions with individual goals. Collaboration based on mutual respect strengthens team performance and directly contributes to improved patient safety, clinical outcomes, and satisfaction in managing high anion gap metabolic acidosis.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol. 1999;37(5):537-60. [PubMed: 10497633]

2.

Adrogué HJ, Madias NE. Management of life-threatening acid-base disorders. First of two parts. N Engl J Med. 1998 Jan 01;338(1):26-34. [PubMed: 9414329]

3.

Bear RA. A clinical approach to the diagnosis of Acid-base disorders. Can Fam Physician. 1986 Apr;32:823-7. [PMC free article: PMC2327641] [PubMed: 21267134]

4.

Chan JC. Acid-base disorders and the kidney. Adv Pediatr. 1983;30:401-71. [PubMed: 6424418]

5.

Kellum JA, Lameire N., KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 04;17(1):204. [PMC free article: PMC4057151] [PubMed: 23394211]

6.

Chong WH, Saha BK, Medarov BI. Comparing Central Venous Blood Gas to Arterial Blood Gas and Determining Its Utility in Critically Ill Patients: Narrative Review. Anesth Analg. 2021 Aug 01;133(2):374-378. [PubMed: 33780397]

7.

Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007 Jan;2(1):162-74. [PubMed: 17699401]

8.

Fenves AZ, Emmett M. Approach to Patients With High Anion Gap Metabolic Acidosis: Core Curriculum 2021. Am J Kidney Dis. 2021 Oct;78(4):590-600. [PubMed: 34400023]

9.

Berend K. Diagnostic Use of Base Excess in Acid-Base Disorders. N Engl J Med. 2018 Apr 12;378(15):1419-1428. [PubMed: 29641969]

10.

Romero JE, Htyte N. An unusual cause of high anion gap metabolic acidosis: pyroglutamic acidemia. A case report. Am J Ther. 2013 Sep-Oct;20(5):581-4. [PubMed: 21519223]

11.

Belkoniene M, Socquet J, Njemba-Freiburghaus D, Pellaton C. Near fatal intoxication by nicotine and propylene glycol injection: a case report of an e-liquid poisoning. BMC Pharmacol Toxicol. 2019 May 10;20(1):28. [PMC free article: PMC6511216] [PubMed: 31077262]

12.

Bielik N, Correia D, Rodrigues Crespo K, Goujon-Ginglinger C, Mitova MI. Pitfalls in the Detection of Volatiles Associated with Heated Tobacco and e-Vapor Products When Using PTR-TOF-MS. J Am Soc Mass Spectrom. 2024 Jun 05;35(6):1261-1271. [PMC free article: PMC11157645] [PubMed: 38780179]

13.

Achanti A, Szerlip HM. Acid-Base Disorders in the Critically Ill Patient. Clin J Am Soc Nephrol. 2023 Jan 01;18(1):102-112. [PMC free article: PMC10101555] [PubMed: 35998977]

14.

Remund B, Yilmaz B, Sokollik C. D-Lactate: Implications for Gastrointestinal Diseases. Children (Basel). 2023 May 26;10(6) [PMC free article: PMC10297508] [PubMed: 37371177]

15.

Barceloux DG, Bond GR, Krenzelok EP, Cooper H, Vale JA., American Academy of Clinical Toxicology Ad Hoc Committee on the Treatment Guidelines for Methanol Poisoning. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. J Toxicol Clin Toxicol. 2002;40(4):415-46. [PubMed: 12216995]

16.

Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med. 1981 Feb 23;141(3 Spec No):364-9. [PubMed: 7469627]

17.

Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009 Oct;67(9):272-83. [PubMed: 19841484]

18.

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43. [PMC free article: PMC2699725] [PubMed: 19564476]

19.

Yoshida N, Takahashi S, Hitaka M, Ohashi Y, Ichibayashi R. Role of Renal Replacement Therapy in Managing Toluene-Induced Acidosis. Am J Case Rep. 2024 Dec 28;25:e945657. [PMC free article: PMC11687328] [PubMed: 39731755]

20.

Tuchscherer J, Rehman H. Metabolic acidosis in toluene sniffing. CJEM. 2013 Jul;15(4):249-52. [PubMed: 23778000]

21.

Di Mauro S, Filippello A, Scamporrino A, Purrello F, Piro S, Malaguarnera R. Metformin: When Should We Fear Lactic Acidosis? Int J Mol Sci. 2022 Jul 28;23(15) [PMC free article: PMC9368510] [PubMed: 35955455]

22.

Tomita D, Bamba Y, Kuwabara N, Akakabe S, Matsubayashi Y, Nakagawa S, Sone H, Nishiyama K. A Case of Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis. J Emerg Med. 2025 Aug;75:222-226. [PubMed: 40537294]

23.

Alexander RT, Bitzan M. Renal Tubular Acidosis. Pediatr Clin North Am. 2019 Feb;66(1):135-157. [PubMed: 30454739]

24.

Kraut JA, Madias NE. Differential diagnosis of nongap metabolic acidosis: value of a systematic approach. Clin J Am Soc Nephrol. 2012 Apr;7(4):671-9. [PMC free article: PMC3315347] [PubMed: 22403272]

25.

Abutalib RA, Alamri AJ, Aqel SA, Alhumaidi IM, Almohini IA. Acute Respiratory Distress and Hyperchloremic Metabolic Acidosis as a Result of Massive Irrigation Fluid Extravasation After Arthroscopic Shoulder Surgery: A Case Report and Recommendations for Preventable Complications. Am J Case Rep. 2020 Nov 13;21:e926357. [PMC free article: PMC7672508] [PubMed: 33184253]

26.

Bhagat H, Singhal V, Dash HH, Mahajan S, Mishra N, Pandia MP. Comparative evaluation of intraoperative use of normal saline, Ringer's lactate, and combination of normal saline and Ringer's lactate in neurosurgical patients - A preliminary randomized clinical trial. Neurol India. 2019 Mar-Apr;67(2):452-458. [PubMed: 31085860]

27.

Nakamura M, Ikeda K, Uezono S. Metabolic acidemia due to saline absorption during transurethral and transcervical surgery: a report of 2 cases. BMC Anesthesiol. 2024 Feb 10;24(1):62. [PMC free article: PMC10858605] [PubMed: 38341531]

28.

Florez ID, Sierra J, Pérez-Gaxiola G. Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children. Cochrane Database Syst Rev. 2023 May 17;5(5):CD013640. [PMC free article: PMC10192509] [PubMed: 37196992]

29.

Hayes W. Ab-normal saline in abnormal kidney function: risks and alternatives. Pediatr Nephrol. 2019 Jul;34(7):1191-1199. [PMC free article: PMC6531391] [PubMed: 29987459]

30.

Pfortmueller C, Funk GC, Potura E, Reiterer C, Luf F, Kabon B, Druml W, Fleischmann E, Lindner G. Acetate-buffered crystalloid infusate versus infusion of 0.9% saline and hemodynamic stability in patients undergoing renal transplantation : Prospective, randomized, controlled trial. Wien Klin Wochenschr. 2017 Sep;129(17-18):598-604. [PMC free article: PMC5599439] [PubMed: 28255797]

31.

Lobo DN, Awad S. Should chloride-rich crystalloids remain the mainstay of fluid resuscitation to prevent 'pre-renal' acute kidney injury?: con. Kidney Int. 2014 Dec;86(6):1096-105. [PMC free article: PMC4255073] [PubMed: 24717302]

32.

Kamar FB, McQuillan RF. Hyperchloremic Metabolic Acidosis due to Cholestyramine: A Case Report and Literature Review. Case Rep Nephrol. 2015;2015:309791. [PMC free article: PMC4573617] [PubMed: 26425378]

33.

Wang Z, Petrovic S, Mann E, Soleimani M. Identification of an apical Cl(-)/HCO3(-) exchanger in the small intestine. Am J Physiol Gastrointest Liver Physiol. 2002 Mar;282(3):G573-9. [PubMed: 11842009]

34.

Ruiz-Sánchez JG, Calle-Pascual AL, Rubio-Herrera MÁ, De Miguel Novoa MP, Gómez-Hoyos E, Runkle I. Clinical manifestations and associated factors in acquired hypoaldosteronism in endocrinological practice. Front Endocrinol (Lausanne). 2022;13:990148. [PMC free article: PMC9592828] [PubMed: 36303866]

35.

Abdalla M, Dave JA, Ross IL. Addison's disease associated with hypokalemia: a case report. J Med Case Rep. 2021 Mar 25;15(1):131. [PMC free article: PMC7992934] [PubMed: 33761983]

36.

Zemlin AE, Sigwadhi LN, Wiese OJ, Jalavu TP, Chapanduka ZC, Allwood BW, Tamuzi JL, Koegelenberg CF, Irusen EM, Lalla U, Ngah VD, Yalew A, Erasmus RT, Matsha TE, Zumla A, Nyasulu PS., COVID-19 Research Response Collaboration. The association between acid-base status and clinical outcome in critically ill COVID-19 patients admitted to intensive care unit with an emphasis on high anion gap metabolic acidosis. Ann Clin Biochem. 2023 Mar;60(2):86-91. [PMC free article: PMC9643107] [PubMed: 36220779]

37.

Chen J, Dai C, Yang Y, Wang Y, Zeng R, Li B, Liu Q. The association between anion gap and in-hospital mortality of post-cardiac arrest patients: a retrospective study. Sci Rep. 2022 May 06;12(1):7405. [PMC free article: PMC9076652] [PubMed: 35524151]

38.

Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010 May;6(5):274-85. [PubMed: 20308999]

39.

Aydın SŞ, Aksakal E. Relationship Between Albumin-Corrected Anion Gap and Mortality in Hospitalized Heart Failure Patients. Cureus. 2023 Sep;15(9):e45967. [PMC free article: PMC10600590] [PubMed: 37900402]

40.

Figge J, Rossing TH, Fencl V. The role of serum proteins in acid-base equilibria. J Lab Clin Med. 1991 Jun;117(6):453-67. [PubMed: 2045713]

41.

Seifter JL, Chang HY. Disorders of Acid-Base Balance: New Perspectives. Kidney Dis (Basel). 2017 Jan;2(4):170-186. [PMC free article: PMC5260542] [PubMed: 28232934]

42.

Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008 Jan;3(1):208-25. [PubMed: 18045860]

43.

Hoffman RS, Smilkstein MJ, Howland MA, Goldfrank LR. Osmol gaps revisited: normal values and limitations. J Toxicol Clin Toxicol. 1993;31(1):81-93. [PubMed: 8433417]

44.

Batlle D, Chin-Theodorou J, Tucker BM. Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap. Am J Kidney Dis. 2017 Sep;70(3):440-444. [PMC free article: PMC5572668] [PubMed: 28599903]

45.

Hanouneh M, Chen TK. Calcium Oxalate Crystals in Ethylene Glycol Toxicity. N Engl J Med. 2017 Oct 12;377(15):1467. [PubMed: 29020580]

46.

Kruse JA. Methanol and ethylene glycol intoxication. Crit Care Clin. 2012 Oct;28(4):661-711. [PubMed: 22998995]

47.

Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med. 2010 Nov 04;363(19):1833-45. [PubMed: 21047227]

48.

Kitabchi AE, Nyenwe EA. Hyperglycemic crises in diabetes mellitus: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am. 2006 Dec;35(4):725-51, viii. [PubMed: 17127143]

49.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. [PubMed: 28101605]

50.

Jaber S, Paugam C, Futier E, Lefrant JY, Lasocki S, Lescot T, Pottecher J, Demoule A, Ferrandière M, Asehnoune K, Dellamonica J, Velly L, Abback PS, de Jong A, Brunot V, Belafia F, Roquilly A, Chanques G, Muller L, Constantin JM, Bertet H, Klouche K, Molinari N, Jung B., BICAR-ICU Study Group. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018 Jul 07;392(10141):31-40. [PubMed: 29910040]

51.

Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Engl J Med. 2009 May 21;360(21):2216-23. [PubMed: 19458366]

52.

Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5. [PubMed: 23737516]

53.

Lee SW, Kim S, Na KY, Cha RH, Kang SW, Park CW, Cha DR, Kim SG, Yoon SA, Han SY, Park JH, Chang JH, Lim CS, Kim YS. Serum Anion Gap Predicts All-Cause Mortality in Patients with Advanced Chronic Kidney Disease: A Retrospective Analysis of a Randomized Controlled Study. PLoS One. 2016;11(6):e0156381. [PMC free article: PMC4889106] [PubMed: 27249416]

54.

Jung B, Martinez M, Claessens YE, Darmon M, Klouche K, Lautrette A, Levraut J, Maury E, Oberlin M, Terzi N, Viglino D, Yordanov Y, Claret PG, Bigé N., Société de Réanimation de Langue Française (SRLF). Société Française de Médecine d’Urgence (SFMU). Diagnosis and management of metabolic acidosis: guidelines from a French expert panel. Ann Intensive Care. 2019 Aug 15;9(1):92. [PMC free article: PMC6695455] [PubMed: 31418093]

55.

Jung B, Rimmele T, Le Goff C, Chanques G, Corne P, Jonquet O, Muller L, Lefrant JY, Guervilly C, Papazian L, Allaouchiche B, Jaber S., AzuRea Group. Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study. Crit Care. 2011;15(5):R238. [PMC free article: PMC3334789] [PubMed: 21995879]

Disclosure: Antoine Kharsa declares no relevant financial relationships with ineligible companies.

Disclosure: Rishik Vashisht declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Rout declares no relevant financial relationships with ineligible companies.

Disclosure: Marcelle Meseeha declares no relevant financial relationships with ineligible companies.